Ziritaxestat

Small molecule

Discontinuedautotaxin (ENPP2)No recent registered activity
Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2021-02-10), on a safety finding

GLPG1690 (ziritaxestat) was the autotaxin inhibitor in the ISABELA Phase 3 programme for idiopathic pulmonary fibrosis. On 10 February 2021 Galapagos and Gilead halted both ISABELA studies (NCT03711162 and NCT03733444) after the Independent Data Monitoring Committee concluded that the benefit-risk profile of ziritaxestat no longer supported continuing them. The systemic sclerosis extension NOVESA-OLE (NCT03976648) was terminated with the same benefit-risk wording. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Other / comorbidity
Phase 2 (3)
Other / comorbidity
NCT03976648 · Lakefront Biotherapeutics NV
2019-07-18 – 2021-04-13 · Systemic Sclerosis
What this study did
NCT03798366 · Lakefront Biotherapeutics NV
2019-01-14 – 2020-06-22 · Systemic Sclerosis
What this study did
NCT02738801 · Lakefront Biotherapeutics NV
2016-03 – 2017-05-02 · Idiopathic Pulmonary Fibrosis
What this study did
Phase 1 (4)
Other / comorbidity
NCT03787186 · Lakefront Biotherapeutics NV
2018-11-09 – 2019-01-17 · Healthy
What this study did
NCT03143712 · Lakefront Biotherapeutics NV
2017-04-18 – 2017-06-14 · Healthy
What this study did
NCT02179502 · Lakefront Biotherapeutics NV
2014-06 – 2014-12 · Healthy
What this study did

Competitive landscape

This drug's own stage for Idiopathic Pulmonary Fibrosis: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ziritaxestat: this drugDiscontinuedSmall moleculeautotaxin (ENPP2)not yet gradedNo reviewed efficacy summary in this indication
Nerandomilast (Jascayd)ApprovedSmall moleculePDE4BReliable signal
NCT05321069: Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 (The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52): Placebo -183.48 Milliliters (mL) (95% CI -210.86 to -156.1) | Nerandomilast 9 mg BID -138.6 Milliliters (mL) (95% CI -165.59 to -111.61) | Nerandomilast 18 mg BID -114.65 Milliliters (mL) (95% CI -141.81 to -87.5)
NCT04419506: The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks (Baseline (day 1) and week 12.): Placebo - Antifibrotics at Baseline -77.7 Milliliter (95% CI -124.87 to -30.53) | BI 1015550 - Antifibrotics at Baseline 2.72 Milliliter (95% CI -33.46 to 38.89) | Placebo - Non-antifibrotics at Baseline -95.62 Milliliter (95% CI -157.13 to -34.1) | BI 1015550 - Non-antifibrotics at Baseline 6.1 Milliliter (95% CI -39.67 to 51.88)
Nintedanib (Ofev)ApprovedSmall moleculeTriple angiokinase inhibitor (VEGFR/FGFR/PDGFR)Partial signal
NCT01335464: INPULSIS-1, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=309) vs placebo (n=204): -114.65 vs -239.91 mL/year; difference 125.26 mL/year (95% CI 77.68 to 172.84), p < 0.0001 (CT.gov posted results).
NCT01335477: INPULSIS-2, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=329) vs placebo (n=219): -113.59 vs -207.32 mL/year; difference 93.73 mL/year (95% CI 44.78 to 142.68), p = 0.0002 (CT.gov posted results).
Pirfenidone (Esbriet)ApprovedSmall moleculePyridoneReliable signal
NCT01366209: At week 52, decline in percent predicted FVC of 10 points or more, or death: pirfenidone 16.5% vs placebo 31.8% (relative reduction 47.9%); no FVC decline 22.7% vs 9.7%; P<0.001 (ASCEND, NEJM 2014; CT.gov posted results).
Treprostinil (Tyvaso DPI)
Approved(overall)
Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
HSK44459Phase 3Small moleculePDE4Bnot yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
ABBV-722
Phase 1(overall)
Small moleculeLPAR1not yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
PamrevlumabDiscontinuedMonoclonal antibodyCTGFnot yet gradedNo reviewed efficacy summary in this indication
Voxelotor (Oxbryta)DiscontinuedSmall moleculeHemoglobin S (HbS)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.